(Q37961846)

26 August 2017

title

Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus (English)

1 reference

26 August 2017

0 references

1 reference

Cara Liday

1

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

31

1 reference

26 August 2017

issue

12 Suppl

1 reference

26 August 2017

page(s)

37S-43S

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Clinical inertia in management of T2DM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Management of patients with type 2 diabetes by pharmacists in primary care clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

The role of the community pharmacist in fulfilling information needs of patients starting oral antidiabetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

An employer-based, pharmacist intervention model for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

Evaluating categorisation and clinical relevance of drug-related problems in medication reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.31.12.37S

21 January 2018

Identifiers

DOI

10.1592/PHCO.31.12.37S

1 reference

release_hum2oisri5gvzevmsheqdjwyra

26 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hum2oisri5gvzevmsheqdjwyra

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference